SIRP alpha-CD70 FUSION PROTEIN AND METHODS OF USE THEREOF
AssigneeKAHR Medical Ltd.
InventorsNoam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
Life of this patent
Estimating the term…
Abstract
SIRPalpha-CD70 fusion proteins are provided. Accordingly, there is provided a SIRPalpha-CD70 fusion protein comprising a single amino acid linker between the SIRPalpha and the CD70. Also there is provided a SIRPalpha-CD70 fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRPalpha-CD70 fusion protein, host-cells expressing the SIRPalpha-CD70 fusion protein and methods of use thereof.
Claims42
A SIRPα-CD70 fusion protein being characterized by a single amino acid linker between said SIRPα and said CD70;
- and/or in a form of at least a homo-trimer.
(canceled)
The SIRPα-CD70 fusion protein of claim 21, wherein said at least homo-trimer is at least 140 kD in molecular weight as determined by SDS-PAGE.
5-6. (canceled)
10-11. (canceled)
(canceled)
21-22. (canceled)
An article of manufacture identified for the treatment of a disease that can benefit from activating immune cells comprising a packaging material packaging a therapeutic agent for treating said disease;
- and a SIRPα-CD70 fusion protein, a polynucleotide encoding same, a nucleic acid construct encoding same or a host cell expressing same.
(canceled)
A method of treating cancer comprising administering to a subject in need thereof an anti-cancer agent;
- and a SIRPα-CD70 fusion protein, a polynucleotide encoding same, a nucleic acid construct encoding same or a host cell expressing same.
31-33. (canceled)
35-36. (canceled)
A method of activating immune cells, the method comprising in-vitro activating immune cells in the presence of a SIRPα-CD70 fusion protein, a polynucleotide encoding same, a nucleic acid construct encoding same or a host cell expressing same.
40-41. (canceled)
(canceled)
(canceled)
49-50. (canceled)
Dependencies are inferred from the claim text.